{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:10:27Z","timestamp":1785190227020,"version":"3.55.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ernest Bazley Foundation","award":["T32AI083216"],"award-info":[{"award-number":["T32AI083216"]}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["T32AI083216"],"award-info":[{"award-number":["T32AI083216"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ear Nose Throat J"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration\u2013approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.<\/jats:p>","DOI":"10.1177\/0145561320964653","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T15:33:16Z","timestamp":1602257596000},"page":"44-47","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps"],"prefix":"10.1177","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-3120","authenticated-orcid":false,"given":"Gayatri B.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"issue":"1","key":"bibr1-0145561320964653","first-page":"S22","volume":"6","author":"Orlandi RR","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"bibr2-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.986"},{"issue":"29","key":"bibr3-0145561320964653","first-page":"1","volume":"58","author":"Fokkens WJ","year":"2020","journal-title":"Rhinology"},{"key":"bibr4-0145561320964653","unstructured":"National Center for Health Statistics, & Centers for Disease Control and Prevention. National Health Interview Survey. Summary Health Statistic Tables for U.S. Adults; 2018. Updated February 21, 2020. Accessed August 19, 2020. https:\/\/www.cdc.gov\/nchs\/fastats\/sinuses.htm"},{"key":"bibr5-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.10.014"},{"key":"bibr6-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.012"},{"key":"bibr7-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27852"},{"key":"bibr8-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.002"},{"key":"bibr9-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.20025"},{"key":"bibr10-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.009"},{"key":"bibr11-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"bibr12-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112374"},{"key":"bibr13-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22473"},{"key":"bibr14-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"bibr15-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"bibr16-0145561320964653","unstructured":"Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps. [press release]. April 2020. 2020."},{"key":"bibr17-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200402-002MS"},{"key":"bibr18-0145561320964653","first-page":"Cd006549","volume":"12","author":"Kalish L","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr19-0145561320964653","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2013.27.3950"},{"key":"bibr20-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21172"},{"key":"bibr21-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLG.0000199741.08517.99"},{"key":"bibr22-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1177\/1945892418810281"},{"key":"bibr23-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.010"},{"key":"bibr24-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22093"},{"key":"bibr25-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.02.020"},{"key":"bibr26-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.03.012"},{"key":"bibr27-0145561320964653","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-5-201103010-00003"},{"key":"bibr28-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-019-0303-6"},{"key":"bibr29-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2010.04.003"},{"key":"bibr30-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"bibr31-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006680"},{"key":"bibr32-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26391"},{"key":"bibr33-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200405000-00004"},{"key":"bibr34-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22487"},{"key":"bibr35-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-020-00332-z"},{"key":"bibr36-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25180"},{"key":"bibr37-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.01.018"},{"key":"bibr38-0145561320964653","unstructured":"Institute for Clinical and Economic Review. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks: final evidence report. Updated December 20, 2018. Accessed August 19, 2020. https:\/\/icerreview.org\/material\/asthma-final-evidence-report\/"},{"key":"bibr39-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/lary.28648"},{"key":"bibr40-0145561320964653","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22633"}],"container-title":["Ear, Nose &amp; Throat Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0145561320964653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0145561320964653","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0145561320964653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:34:02Z","timestamp":1777401242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0145561320964653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/0145561320964653"],"URL":"https:\/\/doi.org\/10.1177\/0145561320964653","relation":{},"ISSN":["0145-5613","1942-7522"],"issn-type":[{"value":"0145-5613","type":"print"},{"value":"1942-7522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}